Beam Therapeutics Inc. (BEAM)
$29.42-$1.06 (-3.48%) Today
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 8 | 351,900 | $12.23M |
| Grant or award | 6 | 118,056 | |
| Option exercise | 10 | 171,010 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
51 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Christine Bellon - Officer | Open-market sale | Common Stock | 1,371 | $34.00 | $47K | |
| Bethany J. Cavanagh - Officer | Open-market sale | Common Stock | 3,034 | $30.12 | $91K | |
| Christine Bellon - Officer | Open-market sale | Common Stock | 2,111 | $33.62 | $71K | |
| Christine Bellon - Officer | Open-market sale | Common Stock | 15,959 | $34.72 | $554K | |
| Christine Bellon - Officer | Open-market sale | Common Stock | 559 | $35.40 | $20K | |
| Sravan Kumar Emany - Officer | Open-market sale | Common Stock | 6,294 | $27.10 | $171K | |
| Christine Bellon - Officer | Open-market sale | Common Stock | 1,254 | $27.10 | $34K | |
| Amy Simon - Officer | Grant or award | Common Stock | 12,500 | $0.00 | - | |
| FMR LLC | Open-market sale | Common Stock | 459 | $26.68 | $12K | |
| FMR LLC | Gift | Common Stock | 1,232,434 | $0.00 | - | |
| John M. Evans - Officer | Option exercise | Common Stock | 25,000 | $0.67 | $17K | |
| John M. Evans - Officer | Open-market sale | Common Stock | 25,000 | $24.51 | $613K | |
| John M. Evans - Officer | Option exercise | Common Stock | 25,000 | $0.67 | $17K | |
| John M. Evans - Officer | Open-market sale | Common Stock | 25,000 | $24.63 | $616K | |
| John M. Evans - Officer | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| John M. Evans - Officer | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Christine Bellon - Officer | Open-market sale | Common Stock | 373 | $24.53 | $9K | |
| Bethany J. Cavanagh - Officer | Open-market sale | Common Stock | 467 | $24.53 | $11K | |
| FMR LLC | Open-market sale | Common Stock | 48,374 | $20.50 | $992K | |
| Amy Simon - Officer | Open-market sale | Common Stock | 374 | $16.94 | $6K | |
| Amy Simon - Officer | Open-market sale | Common Stock | 876 | $20.12 | $18K | |
| John Maraganore | Grant or award | Stock Option (Right to Buy) | 33,662 | $0.00 | - | |
| Giuseppe Ciaramella - Officer | Option exercise | Common Stock | 53,500 | $0.67 | $36K | |
| Giuseppe Ciaramella - Officer | Option exercise | Stock Option (Right to Buy) | 53,500 | $0.00 | - | |
| Chirfi Guindo | Grant or award | Stock Option (Right to Buy) | 39,086 | $0.00 | - | |
| Giuseppe Ciaramella - Officer | Open-market sale | Common Stock | 51,110 | $26.36 | $1.35M | |
| Giuseppe Ciaramella - Officer | Option exercise | Common Stock | 27,318 | $0.67 | $18K | |
| Giuseppe Ciaramella - Officer | Option exercise | Common Stock | 12,979 | $4.22 | $55K | |
| Giuseppe Ciaramella - Officer | Option exercise | Common Stock | 1,457 | $7.22 | $11K | |
| Giuseppe Ciaramella - Officer | Open-market sale | Common Stock | 51,110 | $26.27 | $1.34M | |
| Giuseppe Ciaramella - Officer | Option exercise | Stock Option (Right to Buy) | 27,318 | $0.00 | - | |
| Giuseppe Ciaramella - Officer | Option exercise | Stock Option (Right to Buy) | 12,979 | $0.00 | - | |
| Giuseppe Ciaramella - Officer | Option exercise | Stock Option (Right to Buy) | 1,457 | $0.00 | - | |
| John M. Evans - Officer | Open-market sale | Common Stock | 60,000 | $24.60 | $1.48M | |
| Christine Bellon - Officer | Open-market sale | Common Stock | 385 | $23.48 | $9K | |
| Bethany J. Cavanagh - Officer | Grant or award | Common Stock | 2,500 | $0.00 | - | |
| Bethany J. Cavanagh - Officer | Open-market sale | Common Stock | 289 | $23.48 | $7K |
This is as far as the anonymous view goes. Create a free account for all 51 BEAM filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Beam Therapeutics Inc. (BEAM) had 11 insider filings in the last 90 days, with the most recent on 2026-07-29. The full record for BEAM runs to 51 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of BEAM were filed in the last 90 days.
8 insider sales of BEAM were filed in the last 90 days, totaling $12.23M.
This page tracks BEAM Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add BEAM to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
